March 28
2024
Avacta Group
plc
("Avacta"
or the "Group" or the "Company")
Investor
Webinar
Avacta Group plc (AIM: AVCT), a life
sciences company developing innovative, targeted oncology drugs and
powerful diagnostics, is pleased to announce that
Chief Executive Officer Dr. Alastair Smith will be hosting a webinar on Wednesday, 10
April 2024 at 5:30pm (BST).
The webinar will cover the Company's
updated clinical data from the first-in-human Phase 1 trial of
AVA6000, the first of the Company's pre|CISION™ peptide drug
conjugates that targets chemotherapy to the tumor, which are to be
presented at the 2024 American Association for Cancer Research
Annual Meeting, taking place in San Diego, California from 5-10
April 2024. The updated clinical data will be presented in the
Phase 1 Clinical Trials 2 Poster Session on 9 April
2024.
There will be a Q&A session for
investors after the presentation and questions can be submitted
pre-event as part of the registration process.
You can register for the event by
using the following link:
https://www.turnerpope.com/register/
We are delighted to announce that
the webinar will be chaired by news and corporate events presenter
Katie Pilbeam (www.katiepilbeam.com) and hosted by Turner Pope
Investments.
-Ends-
For
further information from Avacta Group plc, please
contact:
|
Avacta Group plc
Alastair Smith, Chief Executive
Officer
Tony Gardiner, Chief Financial
Officer
Michael Vinegrad, Group
Communications Director
|
Tel: +44
(0) 1904 21 7070
www.avacta.com
|
|
Stifel Nicolaus Europe
Limited (Nomad and Joint Broker)
Nicholas Moore / Nick Adams / Samira
Essebiyea / Nick Harland / Ben Good
|
Tel: +44
(0) 207 710 7600
www.stifel.com
|
|
Peel Hunt (Joint Broker)
James Steel / Chris Golden / Patrick
Birkholm
|
Tel: +44
(0) 207 418 8900
www.peelhunt.com
|
|
ICR Consilium (Media and
IR)
Mary-Jane Elliott / Jessica Hodgson
/ Sukaina Virji
|
avacta@consilium-comms.com
|
|
|
|
|
Webinar enquiries
Turner Pope Investments (TPI)
Limited
James Pope / Andrew
Thacker
|
+44 (0) 20
3657 0050
www.turnerpope.com
|
About Avacta Group plc - https://www.avacta.com
Avacta Group is a UK-based company
focused on improving healthcare outcomes through targeted cancer
treatments and diagnostics.
Avacta has two divisions: an
oncology biotech division harnessing proprietary therapeutic
platforms to develop novel, highly targeted cancer drugs, and a
diagnostics division, focused on supporting healthcare
professionals and broadening access to testing. Avacta's two
proprietary platforms, Affimer® and pre|CISION™ underpin its cancer
therapeutics whilst the diagnostics division leverages the Affimer®
platform to drive competitive advantage in its markets.
The pre|CISION™ platform modifies
chemotherapy to be activated only in the tumor tissue, reducing
systemic exposure and toxicity. This is achieved by harnessing an
enzyme called FAP which is highly upregulated in most solid tumors
compared with healthy tissues, turning chemotherapy into a
"precision medicine". The lead pre|CISION™ programme, AVA6000 a
tumour activated form of doxorubicin, is in Phase 1 studies and has
shown dramatic improvement in safety compared with standard
doxorubicin, and early signs of clinical activity.
To register for news alerts by email
go to https://avacta.com/investors/investor-news-email-alerts/